Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

Xenetic Biosciences, Inc. (XBIO) stock profile

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Key facts

SymbolXBIO
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
CEOJames F. Parslow
Employees2
HeadquartersFramingham, MA, US
IPO2016-06-30
Websitewww.xeneticbio.com

Explore XBIO on Vantafin

  • Xenetic Biosciences, Inc. Overview
  • Xenetic Biosciences, Inc. Financials
  • Xenetic Biosciences, Inc. News
  • Xenetic Biosciences, Inc. Events
  • Xenetic Biosciences, Inc. SEC filings
  • Xenetic Biosciences, Inc. Insider transactions
  • Xenetic Biosciences, Inc. Transcripts

Frequently asked questions

What does Xenetic Biosciences, Inc. (XBIO) do?
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Where is XBIO stock listed?
Xenetic Biosciences, Inc. trades under the ticker XBIO on NASDAQ.
How can I research XBIO's financials and filings?
Vantafin provides Xenetic Biosciences, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the XBIO profile.